Skip to main content

This job has expired

You will need to login before you can apply for a job.

Research Associate I, CMC Analytical

Employer
Precision BioSciences, Inc.
Location
Durham, NC, United States
Start date
Sep 26, 2020

View more

Discipline
Science/R&D, Research
Required Education
Bachelors Degree
Position Type
Full time
Hotbed
Bio NC

Job Details

The Research Associate I, CMC-Analytical Cell Biology, will work in the Cell Therapy Bioassay/Immunoassay/Flow Cytometry group of Precision BioSciences. This individual will provide biologic analytical support for Product Sciences and Cell Therapy Process Development projects. The position will contribute to development efforts for CART-cell projects by providing sample preparation and analysis in a timely manner. This position is lab-based and will share facilities and resources with the Cell Therapy teams.

Essential Duties and Responsibilities

Reasonable accommodations may be made to enable individuals with disabilities to perform the essential functions of this position. This list contains the major duties and requirements of the job and is not all-inclusive. Incumbent(s) may be expected to perform role-related duties other than those contained in this document.

Primary responsibilities will include:
  • Design, development, characterization and documentation of analytical methods for the phenotypic characterization of genome-edited cell therapy products
    • Multi-color Flow Cytometry
    • Immunoassay
    • Bioassay


Qualifications

The requirements listed below are representative of the knowledge, skill, and/or ability required to perform this job successfully.

Education/Experience

Required:
  • Bachelors degree (B.S/B.A.) in the biological sciences
  • At least 1 year of related biopharma industrial experience and/or training


Preferred:
  • Experience in multi-parametric flow cytometry
  • Experience with cellular immunology assay development, including multiplex cytokine analysis and immunological functional assays
  • Background in immunology
  • Experience with mammalian cell culture


Travel Requirements
  • This position requires little to no travel.


Location
  • This is an office-based position located at the main headquarters in downtown Durham, NC.


Precision BioSciences, Inc. is dedicated to improving life by developing advanced tools to edit DNA with a uniquely specific approach. Our proprietary method relies on a single small enzyme, ARC Nuclease, which combines cutting with sequence recognition and can be redesigned to find and edit new target sites across the genome. This simple, powerful gene editing solution allows us to create products that solve not just treat, but solve significant problems in oncology, genetic disease, agriculture, and beyond. Our team includes pioneers in genome editing, leaders in business, and a full staff of talented, committed people who are excited to be a part of the medical and scientific breakthroughs enabled by Precisions next generation gene editing technology. For additional information, please visit www. precisionbiosciences.com

Precision BioSciences provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, gender, sexual orientation, gender identity or expression, national origin, age, disability, genetic information, marital status, amnesty, or status as a covered veteran in accordance with applicable federal, state and local laws. Precision BioSciences complies with applicable state and local laws governing non-discrimination in employment in every location in which the company has facilities. This policy applies to all terms and conditions of employment, including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.

Company

Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing and ex vivo allogeneic CAR T therapies with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly sophisticated edits for gene insertion and/or gene repair. Precision’s in vivo gene editing pipeline consists of wholly-owned preclinical candidates for primary hyperoxaluria type 1 (PBGENE-PH1), familial hypercholesteremia (PBGENE-PCSK9) and chronic hepatitis B (PBGENE-HBV). It has also partnered with Lilly to develop candidates for Duchenne muscular dystrophy and two other programs targeting the liver and CNS. Precision’s allogeneic CAR T pipeline consists of multiple investigational candidates in early-stage clinical trials, including its first and second generation CD19 targeting candidates PBCAR0191 and PBCAR19B for relapsed and/or refractory (R/R) non-Hodgkin and B-cell lymphoma patients. Precision has also prioritized development of PBCAR269A, its BCMA targeted candidate in combination with a gamma secretase inhibitor for R/R patients with multiple myeloma. Precision BioSciences and its in-house manufacturing facility for AAV, mRNA, and CAR T cells is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com

Stock Symbol: DTIL

Stock Exchange: NASDAQ

Company info
Website
Phone
919-314-5512
Location
302 East Pettigrew Street
Durham
North Carolina
27701
US

Get job alerts

Create a job alert and receive personalized job recommendations straight to your inbox.

Create alert